Clinical trial · Observational
Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation
NCT00889278CI-TRIAL-00033049completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine if higher absolute lymphocyte count in the infused stem cell autograft (A-ALC) will lead to an improved antibody response to post-transplant immunization with Pneumococcal Conjugate Vaccine and permit effective immunization at 6 months post-transplant in lymphoma patients receiving Autologous Peripheral Blood Stem Cell Transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Antibody response to vaccination
- timeFrame
- 2 Years
- description
- To assess the antibody response to Prevnar® and its correlation to autograft absolute lymphocyte count (A-ALC).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * Lymphoma or lymphoproliferative disease diagnosis * Scheduled APBSCT * Able to give informed consent and comply with the procedures of the study * Enrollment in other interventional trials are allowed at the discretion of the investigators Exclusion Criteria: * Contraindication to Prevnar® * Has received immune globulin within 5 months prior to being enrolled on the study or plans to receive immune globulin prior to the day +270 (+/-30) visit * Currently participating in, or scheduled to participate in any clinical trial using investigational immune modulators (e.g. IL-2) at any time prior to the completion of follow-up in this study. * Any other underlying medical condition that, in the opinion of the investigator, may interfere with the evaluation of study objectives * Day +180(+/- 30days) Eligibility: * Has received immune globulin within the past 5 months prior to the receipt of the vaccine or plans to receive immune globulin prior to the day +270(+/- 30) visit * Is pregnant (as determined by urine or serum B-HCG test) * Participant has a contraindication to Prevnar® * A recent (\<72 hours) febrile illness (axillary temperature \>99.5°F \[\>37.5°C\], oral temperature \>100.3oF \[\>37.9oC\], or rectal temperature \>101.3°F\[\>38.5°C\]) prior to the study vaccination
References
Publications (0)
Data not yet available
No reference posted for this study.